Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 2/20 | 0.34 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25391785 | 0.86 | ADORA1 (0.42) | NR1H2ADORA1KDM4EMAPTSCN4A | |
| SCHEMBL19549758 | 0.86 | NR1H2 (0.47) | NR1H2ADORA1KDM4EMAPTPRKCI | |
| SCHEMBL30686635 | 0.82 | NR1H2 (0.44) | NR1H2ADORA1KDM4EMAPTPRKCI | |
| SCHEMBL741852 | 0.78 | ADORA1 (0.47) | NR1H2ADORA1KDM4EMAPTSCN4A | |
| SCHEMBL26686516 | 0.77 | MTOR (0.40) | NR1H2ADORA1KDM4EMAPTSCN4A | |
| SCHEMBL172106 | 0.74 | ADORA1 (0.56) | NR1H2ADORA1KDM4EMAPTSCN4A | |
| SCHEMBL23580046 | 0.73 | NR1H2 (0.55) | NR1H2KDM4EMAPTUSP2SMN1; SMN2 | |
| SCHEMBL19549766 | 0.73 | CD274 (0.52) | NR1H2 | |
| SCHEMBL30717643 | 0.73 | NR1H2 (0.37) | NR1H2ADORA1GPR119 | |
| SCHEMBL172107 | 0.72 | ADORA1 (0.43) | NR1H2ADORA1KDM4EMAPTSCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-11608337-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-3452476-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3452476-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210017175-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-01-21 | — | — | US | disclosed |
| US-20210017175-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-01-21 | — | — | US | disclosed |
| US-20200172541-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| US-20200172541-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| EP-3452476-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Holdings Corporation (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20190071439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-03-07 | — | — | US | disclosed |
| US-20190071439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-03-07 | — | — | US | disclosed |
| WO-2017192961-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192961-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | NR1H2 278/4885ADORA1 1316/4885KDM4E 3719/4885 |
| US-20190071439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | NR1H2 278/4885ADORA1 1316/4885KDM4E 3719/4885 |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | NR1H2 278/4885ADORA1 1316/4885KDM4E 3719/4885 |
| US-20200172541-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | NR1H2 278/4885ADORA1 1316/4885KDM4E 3719/4885 |
| US-11608337-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | NR1H2 278/4885ADORA1 1316/4885KDM4E 3719/4885 |
| US-20210017175-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | NR1H2 278/4885ADORA1 1316/4885KDM4E 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.